JW (Cayman) Therapeutics Co. Ltd (2126.HK)
HKD 1.58
(3.27%)
HKD 1.58
(3.27%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -789.6 Million CNY | -13.26% |
| 2022 | -697.17 Million CNY | 9.66% |
| 2021 | -771.71 Million CNY | -64.95% |
| 2020 | -467.86 Million CNY | -129.89% |
| 2019 | -203.51 Million CNY | -81.34% |
| 2018 | -112.23 Million CNY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -247.51 Million CNY | 0.0% |
| 2023 Q2 | -308.53 Million CNY | 0.0% |
| 2023 FY | -789.6 Million CNY | -13.26% |
| 2023 Q4 | -399.68 Million CNY | 0.0% |
| 2022 Q4 | -356.3 Million CNY | 0.0% |
| 2022 FY | -697.17 Million CNY | 9.66% |
| 2022 Q2 | -340.87 Million CNY | 0.0% |
| 2021 FY | -771.71 Million CNY | -64.95% |
| 2021 Q4 | -438.59 Million CNY | 0.0% |
| 2021 Q2 | -333.12 Million CNY | 0.0% |
| 2020 Q2 | -162.42 Million CNY | 0.0% |
| 2020 FY | -467.86 Million CNY | -129.89% |
| 2020 Q4 | -305.43 Million CNY | 0.0% |
| 2019 Q4 | -124.1 Million CNY | 0.0% |
| 2019 Q2 | -79.41 Million CNY | 0.0% |
| 2019 FY | -203.51 Million CNY | -81.34% |
| 2018 Q2 | -67.42 Million CNY | 0.0% |
| 2018 Q1 | -67.42 Million CNY | 0.0% |
| 2018 FY | -112.23 Million CNY | 0.0% |
| 2018 Q4 | -157.97 Million CNY | 0.0% |
| 2017 Q4 | -67.42 Million CNY | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Uni-Bio Science Group Limited | 67.76 Million HKD | 1265.162% |
| CK Life Sciences Int'l., (Holdings) Inc. | 897.95 Million HKD | 187.934% |